Shinpoong Pharmaceutical Co Ltd

Shinpoong Pharmaceutical maintains a strong liquidity position, with a current ratio of 2.8 and cash and equivalents of 47.95 billion KRW, which supports its short-term obligations. The company's liquidity FPT (free cash flow to total liabilities) is robust, indicating a solid ability to meet financial commitments without external financing.

Profitability metrics show a challenging performance, with a net loss of 52.73 million KRW and an operating loss of 4.71 billion KRW. The return on equity (ROE) is negative at -0.02%, and the return on assets (ROA) is similarly weak at -0.02%. These figures fall below the typical performance of the pharmaceutical industry, which generally expects positive ROE and ROA.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the South Korean healthcare market.

Growth prospects are mixed. Revenue for the latest period was 56.03 billion KRW, but the company is not currently showing a clear upward trajectory. The outlook for the next fiscal year is uncertain, with no significant revenue growth expected in the near term.

Risk factors include the company's negative operating and net income, which could impact its ability to sustain operations without external financing. However, the risk of dilution is low, and no immediate filing-based liquidity or dilution flags were detected. The company's debt-to-equity ratio of 0.17 suggests a conservative capital structure.

Recent events include a disclosed net loss and a negative operating income, which may signal underlying operational challenges. No significant regulatory or legal events were reported in the latest filings, and the company's ESG controversies score is 100.00, indicating no major controversies.

Free cash flow surged 266.2% year-over-year to 15.8 billion KRW, demonstrating significant improvement in cash generation capabilities.

Operating income jumped 169.7% to 14.3 billion KRW, marking a decisive turnaround from previous operating losses.

The company achieved best-in-class cash conversion at 107.01%, significantly outperforming the pharmaceutical cohort median of 0.95%.

Net income turned positive with a 157.4% increase, reaching 8.8 billion KRW after years of consistent net losses.

Revenue grew 6.1% year-over-year to 234.7 billion KRW, indicating steady top-line expansion in the current fiscal period.

The company faces high credit risk, signaling potential difficulties in meeting financial obligations or securing favorable financing terms.

Net margin is negative at -0.09%, trailing the pharmaceutical industry median of 3.9% and highlighting profitability challenges.

Long-term debt stands at 55.9 billion KRW, creating leverage exposure despite recent improvements in cash flow generation.

Revenue KRW 200.23B, −4,3% YoY; Operating income −28,5% YoY.

• ▍Revenue KRW 200.23B, −4,3% YoY
• ▍Operating income −28,5% YoY
• ▍Net income −62,0% YoY
• ▍Free cash flow −110,2% YoY
• ▍Net margin -28.6%